期刊文献+

FDA granted accelerated approval to ibrutinib(IMBRUVICA)

FDA granted accelerated approval to ibrutinib(IMBRUVICA)
原文传递
导出
摘要 On Feb.12,2014,the U.S.Food and Drug Administration granted accelerated approval to ibrutinib(IMBRUVICA,Pharmacyclics,Inc.)for the treatment of patients with chronic lymphocytic leukemia(CLL)who have received at least one prior therapy.Ibrutinib previously received accelerated approval on November 13,2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.The approval in CLL was based on the results of a multicenter,singlearm trial of 48 patients with previously treated CLL.The median age was 67 years(range,37 to 82 years)and 71%were male.All patients had a baseline ECOG performance status of 0 or 1.The median time since diagnosis was 6.7 years and the median number of prior treatments was 4(range,1 to 12 treatments).Ibrutinib was administered orally at 420 mg once daily until disease progression or unacceptable toxicity. On Feb. 12. 2014. the U. S. Food (IMBRUVICA, Pharmacyclics, Inc.)for and Drug Administration granted accelerated approval to ibrutinib the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. November 13, 2013 for the treatment of patients one prior therapy Ibrutinib previously received accelerated approval on with mantle cell lymphoma who have received at least
出处 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2014年第4期273-273,共1页 中国药学(英文版)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部